{"contentid": 488720, "importid": NaN, "name": "Further impressive data for Takeda's dengue vaccine", "introduction": "Takeda\u00e2\u0080\u0099s dengue vaccine candidate (TAK-003) has demonstrated continued protection against illness and hospitalization, regardless of a person\u00e2\u0080\u0099s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.", "content": "<p>Takeda&rsquo;s (TYO: 4502) dengue vaccine candidate (TAK-003) has demonstrated continued protection against illness and hospitalization, regardless of a person&rsquo;s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.</p>\n<p>TIDES enrolled more than 20,000 healthy children and adolescents aged four to 16 years in dengue-endemic countries in Latin America and Asia. Safety and efficacy results from the 36-month follow-up exploratory analysis were presented on Saturday.</p>\n<p><span class=\"pullQuote\">\"Our dengue vaccine candidate continued to provide protection against dengue throughout three years\"</span>LakKumar Fernando, center for clinical management of Dengue and Dengue Haemorrhagic Fever, Negombo General Hospital, Sri Lanka and a primary investigator of the TIDES trial, said: &ldquo;Dengue epidemics occur suddenly, and hospitals can become overwhelmed with severe disease cases and people seeking testing.</p>\n<p>&ldquo;Results from the long-term analysis of Takeda&rsquo;s dengue vaccine candidate suggest that it could help with outbreak prevention, reduce rates of hospitalization and protect people from dengue regardless of their previous exposure. Importantly, no important safety risks were identified.&rdquo;</p>\n<p>Derek Wallace, dengue global program leader at Takeda, added: &ldquo;Our dengue vaccine candidate continued to provide protection against dengue throughout three years, and was especially robust in preventing hospitalization.&rdquo;</p>\n<p>TIDES safety and efficacy data through 36-months follow-up was included in regulatory submissions to the European Union and dengue-endemic countries and will be part of additional filings planned for 2021, including in the USA.</p>\n<p>The Japanese drugmaker will seek an indication for TAK-003 for the prevention of dengue disease in individuals four to 60 years of age, regardless of previous virus exposure, based on data in both adults and children. There remains a need for dengue vaccines that can be used in both dengue-na&iuml;ve and dengue-exposed adults and children.</p>", "date": "2021-05-24 17:12:00", "meta_title": NaN, "meta_keywords": "dengue, vaccine, years, candidate, TIDES, safety, continued, protection, efficacy, hospitalization, exposure, previous, trial, identified, risks, data, TAK", "meta_description": "Takeda\u00e2\u0080\u0099s dengue vaccine candidate (TAK-003) has demonstrated continued protection against illness and hospitalization.regardless of a person\u00e2\u0080\u0099s previous dengue e", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-24 17:10:42", "updated": "2021-05-24 17:28:56", "access": NaN, "url": "https://www.thepharmaletter.com/article/further-impressive-data-for-takeda-s-dengue-vaccine", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "dengue_mosquito_large.jpg", "image2id": "dengue_mosquito_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Drug Trial", "geography_tag": "Japan", "company_tag": "Takeda", "drug_tag": "TAK-003", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-24 17:12:00"}